The safety risks of innovation: The FDA's expedited drug development pathway

Thomas J. Moore; Curt D. Furberg

doi:10.1001/jama.2012.9658

The safety risks of innovation: The FDA's expedited drug development pathway

Thomas J. Moore, Curt D. Furberg

Research output: Contribution to journal › Short survey › peer-review

Original language	English (US)
Pages (from-to)	869-870
Number of pages	2
Journal	JAMA
Volume	308
Issue number	9
DOIs	https://doi.org/10.1001/jama.2012.9658
State	Published - Aug 29 2012
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1001/jama.2012.9658

Cite this

@article{379e9dd79a44482ba2bbd1cbf0a91fad,

title = "The safety risks of innovation: The FDA's expedited drug development pathway",

author = "Moore, {Thomas J.} and Furberg, {Curt D.}",

year = "2012",

month = aug,

day = "29",

doi = "10.1001/jama.2012.9658",

language = "English (US)",

volume = "308",

pages = "869--870",

journal = "JAMA",

issn = "0098-7484",

publisher = "American Medical Association",

number = "9",

}

TY - JOUR

T1 - The safety risks of innovation

T2 - The FDA's expedited drug development pathway

AU - Moore, Thomas J.

AU - Furberg, Curt D.

PY - 2012/8/29

Y1 - 2012/8/29

UR - http://www.scopus.com/inward/record.url?scp=84865700868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865700868&partnerID=8YFLogxK

U2 - 10.1001/jama.2012.9658

DO - 10.1001/jama.2012.9658

M3 - Short survey

C2 - 22948694

AN - SCOPUS:84865700868

SN - 0098-7484

VL - 308

SP - 869

EP - 870

JO - JAMA

JF - JAMA

IS - 9

ER -

The safety risks of innovation: The FDA's expedited drug development pathway

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this